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The International Staging Project of the International Association for the Study of LungCancer (IASLC)1 created a data base containing information on over 100,000 cases of
lung cancers, enrolled between 1990 and 2000, treated by all modalities of care, from over
46 data bases in over 19 countries around the world. The analysis of this data has informed
the forthcoming 7th edition of TNM in Lung Cancer, and has resulted in 13 peer-reviewed
articles in the Journal of Thoracic Oncology.2–14 The thrust of these articles has
understandably focused on staging issues in non-small cell lung cancer, small-cell lung
cancer, and carcinoid tumors. However, there has been one other study by a member of
the committee which has demonstrated the possibility of using this data for purposes other
than that for which it was collected by the IASLC.15 Now that this first phase of the project
is complete the committee will be focusing on accumulating more retrospective and
prospective data to inform the 8th edition of TNM and beyond. However, the committee
feels that it has a responsibility to the IASLC, the contributing data bases, the lung cancer
community and, not least, patients and their relatives around the world, to offer this data
base for wider secondary uses. The committee has developed guide lines on this use:
All requests for the secondary use of the database will be subjected to the following
review mechanism:
An initial, outline proposal should be submitted to the chair of the committee. This
will be reviewed by e-mail by a subcommittee consisting of the chair person, a member
of our statistical team at Cancer Research And Biostatistics (CRAB) and the chair of the
relevant subcommittee. If the request is considered to be of value, and one which can be
addressed by the data base, the applicant will be asked to submit a full application
containing the following, additional documentation:
a. A full proposal setting out the details of the study, methods, population under study,
data required from the database and proposed time lines.
b. A full list of the participants to the study and proposals for involvement by members
of the committee and CRAB. The study should include as primary authors at least one
medical member of the committee and one CRAB member of the committee.
c. A supportive letter from CRAB confirming that the necessary data is obtainable from
the data base and that the quality and volume of that data is adequate to answer the
question posed.
d. All raw data will remain in the IASLC database and all extraction, analysis and
validation will be conducted by CRAB. The application must be accompanied by an
estimate from CRAB of the additional costs of extracting and analyzing the data. The
applicant must explain all sources of funding and give assurances that the committee
will be reimbursed for the additional cost of this work unless, in exceptional circum-
stances, the committee agrees to waive such charges.
e. Confirmation that the applicant and all other parties who may be considered to hold
intellectual property rights will adhere to the highest scientific and ethical standards,
including but not exclusively:
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a. Will respect the IASLC ownership of the data and will
not seek to use the information provided for any other use
without the agreement of the IASLC.
b. Will respect the anonymity of the clinical data.
c. Will submit any publication or presentation for scrutiny
by the committee, and in addition, by those database
proprietors with whom there exists prior agreements,
before submission. The committee reserves the right to
deny publication in extreme situations.
d. Will publish any submission in a format agreed with the
committee, including the format of the title, and ac-
knowledging the participation of the IASLC, the com-
mittee members, CRAB and the database proprietors.
The acknowledgment of our sponsors will be recognized
in a format agreed with them from time to time.
e. Will submit publications, in the first place, to the Journal
of Thoracic Oncology, the official journal of the IASLC.
In exceptional circumstances this requirement may be
waived if, in the opinion of the committee, another
journal is more appropriate for the format or topic under
study.
The full proposal will be circulated to the full commit-
tee by e-mail and the committee’s view collected by the
chairman. If consensus cannot be reached using electronic
mail the proposal will be discussed at the next meeting of the
committee. Revisions or additional material may be requested
before a final decision is reached. The committee’s decision
is final and there will be no appeal structure.
The data fields contained within the data base, and other
information, can be obtained by e-mailing information@crab.
org with “IASLC Staging Project” in the subject line.
All applications should be sent to the chairman, Peter
Goldstraw, at p.goldstraw@rbht.nhs.uk or the vice-chair, Dr.
Ramon Rami-Porta at rramip@terra.es. We look forward to
receiving your proposals. While our first obligation is to those
who contributed data to the project, proposals from all other
individuals will be considered on merit.
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